Research ExplorerPublicationsCorrelation of biomarkers of endothelium dysfunction and mat...

Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.

Standard

Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. / Blaise, Sophie; Maas, Renke; Trocme, Candice; Kom, Ghainsom D; Roustit, Matthieu; Carpentier, Patrick H; Cracowski, Jean-Luc.

In: J RHEUMATOL, Vol. 36, No. 5, 5, 2009, p. 984-988.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Blaise, S, Maas, R, Trocme, C, Kom, GD, Roustit, M, Carpentier, PH & Cracowski, J-L 2009, 'Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.', J RHEUMATOL, vol. 36, no. 5, 5, pp. 984-988. <http://www.ncbi.nlm.nih.gov/pubmed/19332631?dopt=Citation>

APA

Blaise, S., Maas, R., Trocme, C., Kom, G. D., Roustit, M., Carpentier, P. H., & Cracowski, J-L. (2009). Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J RHEUMATOL, 36(5), 984-988. [5]. http://www.ncbi.nlm.nih.gov/pubmed/19332631?dopt=Citation

Vancouver

Blaise S, Maas R, Trocme C, Kom GD, Roustit M, Carpentier PH et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J RHEUMATOL. 2009;36(5):984-988. 5.

Bibtex

@article{52f7461ab23b496ab39b352b14121a55,
title = "Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.",
abstract = "OBJECTIVE: Systemic sclerosis (SSc) is a multisystem disease characterized by microvascular dysfunction and excessive fibrosis. However, the relationship between these 2 features remains unclear. Endothelial dysfunction can be assessed by quantifying plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. Matrix remodeling can be assessed by quantifying serum tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Both biomarkers are elevated in patients with SSc. Our objective was to test whether plasma ADMA is correlated with serum TIMP-1. METHODS: We enrolled 91 subjects, 39 patients with SSc, 28 patients with primary Raynaud's phenomenon (RP), and 24 healthy volunteers. Plasma ADMA concentrations were measured by liquid chromatography-tandem mass spectrometry. Serum TIMP-1 concentrations were determined by ELISA. RESULTS: Mean ADMA concentrations were higher in patients with SSc (0.68 microM +/- 0.12) than in patients with primary RP or healthy volunteers (respectively, 0.56 microM +/- 0.14 and 0.62 microM +/- 0.12; p = 0.002). Median serum TIMP-1 concentrations were increased in patients with SSc compared to primary RP and healthy volunteers [12 (9-15), 11 (8-13), and 10 (7-13) nM, respectively; p = 0.05]. In the SSc group, we observed a statistically significant correlation between plasma ADMA and serum TIMP-1 (r = 0.34, p = 0.035). CONCLUSION: These data are consistent with our hypothesis of an association of endothelial dysfunction and matrix remodeling in scleroderma spectrum disorders.",
keywords = "Humans, Male, Female, Middle Aged, inhibitors, derivatives, Arginine analogs, Biological Markers metabolism, Endothelium, Vascular metabolism, Enzyme Inhibitors metabolism, Extracellular Matrix metabolism, Nitric Oxide Synthase antagonists, Raynaud Disease metabolism, Regional Blood Flow physiology, Scleroderma, Systemic metabolism, Skin blood supply, Tissue Inhibitor of Metalloproteinase-1 metabolism, Humans, Male, Female, Middle Aged, inhibitors, derivatives, Arginine analogs, Biological Markers metabolism, Endothelium, Vascular metabolism, Enzyme Inhibitors metabolism, Extracellular Matrix metabolism, Nitric Oxide Synthase antagonists, Raynaud Disease metabolism, Regional Blood Flow physiology, Scleroderma, Systemic metabolism, Skin blood supply, Tissue Inhibitor of Metalloproteinase-1 metabolism",
author = "Sophie Blaise and Renke Maas and Candice Trocme and Kom, {Ghainsom D} and Matthieu Roustit and Carpentier, {Patrick H} and Jean-Luc Cracowski",
year = "2009",
language = "Deutsch",
volume = "36",
pages = "984--988",
journal = "J RHEUMATOL",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

RIS

TY - JOUR

T1 - Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis.

AU - Blaise, Sophie

AU - Maas, Renke

AU - Trocme, Candice

AU - Kom, Ghainsom D

AU - Roustit, Matthieu

AU - Carpentier, Patrick H

AU - Cracowski, Jean-Luc

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: Systemic sclerosis (SSc) is a multisystem disease characterized by microvascular dysfunction and excessive fibrosis. However, the relationship between these 2 features remains unclear. Endothelial dysfunction can be assessed by quantifying plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. Matrix remodeling can be assessed by quantifying serum tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Both biomarkers are elevated in patients with SSc. Our objective was to test whether plasma ADMA is correlated with serum TIMP-1. METHODS: We enrolled 91 subjects, 39 patients with SSc, 28 patients with primary Raynaud's phenomenon (RP), and 24 healthy volunteers. Plasma ADMA concentrations were measured by liquid chromatography-tandem mass spectrometry. Serum TIMP-1 concentrations were determined by ELISA. RESULTS: Mean ADMA concentrations were higher in patients with SSc (0.68 microM +/- 0.12) than in patients with primary RP or healthy volunteers (respectively, 0.56 microM +/- 0.14 and 0.62 microM +/- 0.12; p = 0.002). Median serum TIMP-1 concentrations were increased in patients with SSc compared to primary RP and healthy volunteers [12 (9-15), 11 (8-13), and 10 (7-13) nM, respectively; p = 0.05]. In the SSc group, we observed a statistically significant correlation between plasma ADMA and serum TIMP-1 (r = 0.34, p = 0.035). CONCLUSION: These data are consistent with our hypothesis of an association of endothelial dysfunction and matrix remodeling in scleroderma spectrum disorders.

AB - OBJECTIVE: Systemic sclerosis (SSc) is a multisystem disease characterized by microvascular dysfunction and excessive fibrosis. However, the relationship between these 2 features remains unclear. Endothelial dysfunction can be assessed by quantifying plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase. Matrix remodeling can be assessed by quantifying serum tissue inhibitor of matrix metalloproteinases-1 (TIMP-1). Both biomarkers are elevated in patients with SSc. Our objective was to test whether plasma ADMA is correlated with serum TIMP-1. METHODS: We enrolled 91 subjects, 39 patients with SSc, 28 patients with primary Raynaud's phenomenon (RP), and 24 healthy volunteers. Plasma ADMA concentrations were measured by liquid chromatography-tandem mass spectrometry. Serum TIMP-1 concentrations were determined by ELISA. RESULTS: Mean ADMA concentrations were higher in patients with SSc (0.68 microM +/- 0.12) than in patients with primary RP or healthy volunteers (respectively, 0.56 microM +/- 0.14 and 0.62 microM +/- 0.12; p = 0.002). Median serum TIMP-1 concentrations were increased in patients with SSc compared to primary RP and healthy volunteers [12 (9-15), 11 (8-13), and 10 (7-13) nM, respectively; p = 0.05]. In the SSc group, we observed a statistically significant correlation between plasma ADMA and serum TIMP-1 (r = 0.34, p = 0.035). CONCLUSION: These data are consistent with our hypothesis of an association of endothelial dysfunction and matrix remodeling in scleroderma spectrum disorders.

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - inhibitors

KW - derivatives

KW - Arginine analogs

KW - Biological Markers metabolism

KW - Endothelium, Vascular metabolism

KW - Enzyme Inhibitors metabolism

KW - Extracellular Matrix metabolism

KW - Nitric Oxide Synthase antagonists

KW - Raynaud Disease metabolism

KW - Regional Blood Flow physiology

KW - Scleroderma, Systemic metabolism

KW - Skin blood supply

KW - Tissue Inhibitor of Metalloproteinase-1 metabolism

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - inhibitors

KW - derivatives

KW - Arginine analogs

KW - Biological Markers metabolism

KW - Endothelium, Vascular metabolism

KW - Enzyme Inhibitors metabolism

KW - Extracellular Matrix metabolism

KW - Nitric Oxide Synthase antagonists

KW - Raynaud Disease metabolism

KW - Regional Blood Flow physiology

KW - Scleroderma, Systemic metabolism

KW - Skin blood supply

KW - Tissue Inhibitor of Metalloproteinase-1 metabolism

M3 - SCORING: Zeitschriftenaufsatz

VL - 36

SP - 984

EP - 988

JO - J RHEUMATOL

JF - J RHEUMATOL

SN - 0315-162X

IS - 5

M1 - 5

ER -